Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on the development of regenerative medicine and immunotherapy-based treatments. The company operates within the biotechnology and cellular therapy industries, with an emphasis on leveraging stem cell technologies and immune modulation to address chronic and unmet medical conditions. Creative Medical Technology Holdings, Inc. does not currently generate material commercial revenue and primarily operates as a research and development organization.
The company’s core focus areas include autologous and allogeneic cell therapies targeting conditions such as erectile dysfunction, female sexual dysfunction, neurological disorders, and certain immune-mediated diseases. Its strategic positioning centers on developing minimally manipulated cell-based therapies that may qualify for streamlined regulatory pathways. Creative Medical Technology Holdings, Inc. was founded in 2016 and has since evolved through the acquisition of intellectual property and the formation of subsidiaries to advance its clinical pipeline.
Business Operations
Creative Medical Technology Holdings, Inc. conducts its operations through multiple wholly owned subsidiaries that manage distinct technology platforms and clinical programs, including Creative Medical Technologies, Inc., Creative Medical Health, Inc., and ImmCelz, Inc. The company’s business model is centered on advancing product candidates through preclinical research and early-stage clinical trials, with future revenue generation expected from commercialization, licensing, or strategic partnerships if regulatory approvals are achieved.
Operations are primarily research-focused and largely based in the United States, with clinical activities conducted through contracted research organizations and clinical partners. The company controls a portfolio of patents and patent applications related to stem cell treatments, immune-modulatory therapies, and regenerative medicine technologies. There is no verified evidence of large-scale manufacturing or commercial distribution activities as of the most recent public filings.
Strategic Position & Investments
The company’s strategic direction emphasizes expanding its clinical pipeline in regenerative medicine and immunotherapy while seeking non-dilutive funding opportunities, strategic collaborations, or licensing arrangements. Growth initiatives have included the acquisition of intellectual property and the internal development of therapeutic platforms such as ImmCelz-based immune modulation and cell therapy programs addressing urological and neurological indications.
Creative Medical Technology Holdings, Inc. has historically pursued acquisitions of early-stage technologies rather than revenue-generating businesses. Notable investments have primarily taken the form of patent purchases and subsidiary formation rather than large-scale mergers or acquisitions. Data inconclusive based on available public sources regarding any material equity investments in external portfolio companies or late-stage clinical assets.
Geographic Footprint
Creative Medical Technology Holdings, Inc. is headquartered in the United States, with its principal executive offices located in Arizona. The company’s operational footprint is predominantly domestic, reflecting its status as a clinical-stage biotechnology firm with centralized management and research oversight.
While the company references potential global applicability of its technologies, there is limited verified public information confirming material international operations, overseas subsidiaries, or foreign manufacturing capabilities. Any international clinical or commercial expansion remains prospective based on available disclosures.
Leadership & Governance
The company is led by a management team with experience in biotechnology, healthcare, and corporate finance, with governance oversight provided by a board of directors. Leadership has articulated a strategic vision centered on advancing regenerative medicine therapies through capital-efficient development and regulatory positioning.
Key executives include:
- Timothy Warbington – Chief Executive Officer
- John Bradford – Chief Financial Officer
- Robert E. Hariri, MD, PhD – Scientific Advisor and Board Member
- Amir Zarrabi – Chairman of the Board
The leadership team emphasizes innovation in cell-based therapeutics while maintaining a focus on intellectual property development and early-stage clinical validation.